(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.39%) $79.26
(-0.34%) $2.03
(0.08%) $2 311.40
(0.25%) $26.90
(0.37%) $966.20
(-0.04%) $0.932
(-0.11%) $10.98
(-0.09%) $0.797
(-0.03%) $91.10
Live Chart Being Loaded With Signals
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...
Stats | |
---|---|
Šios dienos apimtis | 1.46M |
Vidutinė apimtis | 798 146 |
Rinkos kapitalizacija | 65.08M |
EPS | $0 ( 2024-03-07 ) |
Kita pelno data | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.686 |
ATR14 | $0.0570 (5.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
INSIDER POWER |
---|
-73.69 |
Last 94 transactions |
Buy: 4 462 585 | Sell: 5 534 482 |
Tūris Koreliacija
Surface Oncology Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ISO | 0.841 |
ARQT | 0.833 |
ALLO | 0.827 |
ALVR | 0.818 |
DVAX | 0.818 |
BGFV | 0.816 |
ENNV | 0.815 |
LQDT | 0.805 |
ALZN | 0.805 |
CARE | 0.804 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Surface Oncology Inc Koreliacija - Valiuta/Žaliavos
Surface Oncology Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $30.00M |
Bruto pelnas: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2022 |
Pajamos: | $30.00M |
Bruto pelnas: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2021 |
Pajamos: | $2.69M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.735 |
FY | 2020 |
Pajamos: | $126.16M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $1.670 |
Financial Reports:
No articles found.
Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.